Hit-to-lead
studies employ a variety of strategies to optimize
binding to a target of interest. When a structure for the target is
available, hypothesis-driven structure–activity relationships
(SAR) are a powerful strategy for refining the pharmacophore to achieve
robust binding and selectivity characteristics necessary to identify
a lead compound. Recrafting the three-dimensional space occupied by
a small molecule, optimization of hydrogen bond contacts, and enhancing
local attractive interactions are traditional approaches in medicinal
chemistry. Ring size, however, is rarely able to be leveraged as an
independent variable because most hits lack the symmetry required
for such a study. Our discovery that the cyclic oligomeric depsipeptide ent-verticilide inhibits mammalian cardiac ryanodine receptor
calcium release channels with submicromolar potency provided an opportunity
to explore ring size as a variable, independent of other structural
or functional group changes. We report here that ring size can be
a critical independent variable, suggesting that modest conformational
changes alone can dramatically affect potency.